Emirates Drug Establishment Approves Tapinarof Cream 1%, A New Treatment For Plaque Psoriasis In Adults And Atopic Dermatitis ...

Still itching after topical steroids? Here's why your atopic dermatitis symptoms may still be flaring and what you can do about it.

Ruxolitinib cream demonstrated favorable safety and efficacy in pediatric atopic dermatitis, highlighting JAK inhibitors' ...

Moderate-to-severe atopic dermatitis is associated with higher lifetime prevalence of multimorbidity and increased odds of ...

Rocatinlimab improved moderate to severe dermatitis in adults, establishing the OX40 receptor as a validated treatment target ...

Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase ...

In spite of its commonality, there are still plenty of unknowns around atopic dermatitis, including the actual cause of the skin condition. Perhaps that’s why there are so many myths surrounding it.

Kymera Therapeutics receives US FDA Fast Track Designation for KT-621, an oral STAT6 degrader to treat atopic dermatitis: Watertown, Massachusetts Saturday, December 13, 2025, 18: ...

Children saw improvements in their atopic dermatitis with tapinarof regardless of their atopic comorbidities, according to ...

Kymera Therapeutics has announced positive results from its trial of KT-621 to treat patients with moderate to severe atopic ...

Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics (R) , today announced the close of its $25 million, twice-oversubscribed Series B ...